Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New appointment at Pro-Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Pro-Pharmaceuticals (US) has named Dr Peter Traber acting chief medical officer. He will lead the Phase III colorectal cancer trial for the company's lead product candidate, Davanat, a polysaccharide polymer that targets Galectin receptors, as well as the overall US FDA approval process. Dr Traber, who has served as senior vice-president for clinical development and medical affairs and as chief medical officer at GlaxoSmithKline, was elected to Pro-Pharmaceuticals' board of directors in 2009. He will retain this position but will not be a full-time employee of the company.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts